市場調查報告書
商品編碼
1182210
耳鼻喉科治療全球市場規模研究和預測,按藥物類型(抗生素藥物,抗炎藥物等),器官(喉嚨,耳朵,鼻子),用戶(醫院和診所,家庭保健場所,其他)區域分析2022-2029Global ENT Disorder Treatment Market Size study & Forecast, by Drug Type (Antibiotics Drugs, Anti Inflammatory Drugs, Others), by Organ (Throat, Ear, Nose), by End User (Hospital & clinics, Homecare Settings, Others) & Regional Analysis, 2022-2029 |
2021 年全球耳鼻喉疾病治療市場價值約為 24 億美元,預計在 2022-2029 年預測期內將以超過 6.5% 的健康增長率增長。
耳鼻喉科是指由細菌和病毒引起的與耳朵、鼻子和喉嚨相關的感染。 耳部感染可導致聽力下降、耳痛和耳部分泌物。 另一方面,鼻子和喉嚨的疾病會導致喉嚨痛、流鼻涕、打鼾、睡眠呼吸暫停綜合症和呼吸困難。 此外,耳鼻喉科疾病的治療方法多種多樣,包括抗生素、消炎藥等。 老年人口的增加、傳染病的流行以及各大公司的戰略舉措是加速市場增長的主要因素。
世界衛生組織 (WHO) - 根據 2019 年的數據,全球約有 260 萬人死於下呼吸道感染。 此外,澳大利亞健康與福利研究所估計,在 -2020-21 財年,澳大利亞因傳染病住院的人數超過 324,000 人,其中約 94% 為非法定上報疾病。 此外,全球污染水平上升和發展中地區醫療成本上升將為預測期內的市場創造良好的增長前景。 然而,醫療器械的高成本將阻礙整個 2022-2029 年預測期內的市場增長。
耳鼻喉科治療全球市場研究考慮的主要區域包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於強大的市場參與者的存在以及該地區傳染病流行的加劇等因素,北美已成為市場份額的主要地區。 另一方面,由於老年人口增加和呼吸系統疾病增加等因素,預計亞太地區在預測期內將顯著增長。
這項研究的目的是揭示近年來各個細分市場和國家/地區的市場規模,並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。
按藥物類型
抗生素藥物
抗炎藥
雜項
按器官
喉嚨
耳朵
鼻子
最終用戶
醫院/診所
家庭醫療網站
雜項
Global ENT Disorder Treatment Market is valued approximately USD 2.4 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. ENT Disorder refers to infections associated with ear, nose and throat that caused by bacteria and viruses. Ear infection can cause hearing loss, earache, discharge from ear. Whereas nose & throat disorders can cause sore throat, runny nose, snoring, sleep apnea, and breathing difficulty among others. Moreover, there are different treatment options available for ENT disorders including antibiotics, anti- inflammatory drugs etc. The increasing number of geriatric individuals and growing prevalence of infectious diseases as well as strategic initiatives from leading market players are key factors accelerating the market growth.
According to the World Health Organization (WHO) - in 2019, globally approximately 2.6 million individuals lost their lives due to lower respiratory infections. Moreover, as per Australian Institute of Health and Welfare estimates - in financial year 2020-21, Australia witnessed more than 324,000 hospitalizations for infectious diseases, out of which around 94% were for non-notifiable diseases. Also, growing pollution levels worldwide and rising healthcare spending in developing regions would create lucrative growth prospectus for the market over the forecast period. However, the high cost of medical devices impedes the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global ENT Disorder Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as presence of leading market players and growing prevalence of infectious diseases in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population as well as increasing incidences of respiratory disorders in the region.
Major market players included in this report are:
Sanofi
Novartis
GSK
Pfizer
Vitaris
Sun Pharma
AstraZeneca
Cipla
AurbindoPharma
Teva Pharmaceuticals
Recent Developments in the Market:
Global ENT Disorder Treatment Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Drug Type, Organ, End User, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type
Antibiotics Drugs
Anti-Inflammatory Drugs
Others
By Organ
Throat
Ear
Nose
By End User
Hospital and clinics
Homecare Settings
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable